|
US6015555A
(en)
*
|
1995-05-19 |
2000-01-18 |
Alkermes, Inc. |
Transferrin receptor specific antibody-neuropharmaceutical or diagnostic agent conjugates
|
|
US7629309B2
(en)
|
2002-05-29 |
2009-12-08 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
EP1436316B1
(en)
|
2001-04-30 |
2008-01-23 |
ZyStor Therapeutics , Inc. |
Subcellular targeting of therapeutic proteins
|
|
US7560424B2
(en)
|
2001-04-30 |
2009-07-14 |
Zystor Therapeutics, Inc. |
Targeted therapeutic proteins
|
|
US20030072761A1
(en)
|
2001-10-16 |
2003-04-17 |
Lebowitz Jonathan |
Methods and compositions for targeting proteins across the blood brain barrier
|
|
WO2003057179A2
(en)
|
2002-01-11 |
2003-07-17 |
Biomarin Pharmaceutical, Inc. |
Use of p97 as an enzyme delivery system for the delivery of therapeutic lysosomal enzymes
|
|
CN102268094A
(zh)
*
|
2002-08-30 |
2011-12-07 |
比奥雷克西斯药物公司 |
被修饰的转铁蛋白抗体的融合蛋白
|
|
US7388079B2
(en)
|
2002-11-27 |
2008-06-17 |
The Regents Of The University Of California |
Delivery of pharmaceutical agents via the human insulin receptor
|
|
US20050142141A1
(en)
*
|
2002-11-27 |
2005-06-30 |
Pardridge William M. |
Delivery of enzymes to the brain
|
|
CN110496230A
(zh)
|
2003-02-11 |
2019-11-26 |
夏尔人类遗传性治疗公司 |
使用甲酰-甘氨酸生成酶(fge)对多种硫酸酯酶缺乏症和其它病症进行诊断和治疗
|
|
US20040258666A1
(en)
|
2003-05-01 |
2004-12-23 |
Passini Marco A. |
Gene therapy for neurometabolic disorders
|
|
AU2003286870A1
(en)
|
2003-06-05 |
2005-01-04 |
Salk Institute For Biological Studies |
Targeting polypeptides to the central nervous system
|
|
US20050026823A1
(en)
|
2003-06-20 |
2005-02-03 |
Biomarin Pharmaceutical Inc. |
Use of the chaperone receptor-associated protein (RAP) for the delivery of therapeutic compounds to the brain and other tissues
|
|
US7442372B2
(en)
|
2003-08-29 |
2008-10-28 |
Biomarin Pharmaceutical Inc. |
Delivery of therapeutic compounds to the brain and other tissues
|
|
BRPI0406605B8
(pt)
|
2003-11-13 |
2021-05-25 |
Hanmi Holdings Co Ltd |
conjugado de proteína, método para a preparação do mesmo e composição farmacêutica para intensificar a duração e estabilidade in vivo de um polipeptídeo fisiologicamente ativo
|
|
EP1697520A2
(en)
|
2003-12-22 |
2006-09-06 |
Xencor, Inc. |
Fc polypeptides with novel fc ligand binding sites
|
|
NZ576986A
(en)
|
2004-01-30 |
2010-12-24 |
Shire Pharmaceuticals Ireland Ltd |
Production and purification of recombinant arylsulfatase A
|
|
WO2006007560A2
(en)
|
2004-07-01 |
2006-01-19 |
University Of Pennsylvania |
Targeted protein replacement for the treatment of lysosomal storage disorders
|
|
ATE423140T1
(de)
|
2005-01-05 |
2009-03-15 |
F Star Biotech Forsch & Entw |
Synthetische immunoglobulindomänen mit in regionen des moleküls, die sich von den die komplementarität bestimmenden bereichen unterscheiden, modifizierten bindeeigenschaften
|
|
JP5137814B2
(ja)
|
2005-04-06 |
2013-02-06 |
ジェンザイム・コーポレーション |
治療ターゲティングのための酸不安定リンカーを介するpegおよびポリシアルリソソーム酵素のコンジュゲート
|
|
AR059089A1
(es)
|
2006-01-20 |
2008-03-12 |
Genzyme Corp |
Administracion intraventricular de una enzima para enfermedades de almacenamiento lisosomal
|
|
CA2641070C
(en)
|
2006-02-06 |
2017-01-03 |
Ramot At Tel-Aviv University Ltd. |
Enzyme replacement therapy for treating lysosomal storage diseases
|
|
WO2008054544A2
(en)
|
2006-05-22 |
2008-05-08 |
Immune Disease Institute, Inc. |
Method for delivery across the blood brain barrier
|
|
US7871624B2
(en)
*
|
2006-06-27 |
2011-01-18 |
Saint Louis University |
Chimeral polypeptide composition for cross-placenta delivery
|
|
WO2008105796A2
(en)
|
2006-06-29 |
2008-09-04 |
Albert Einstein College Of Medicine Of Yeshiva University |
Compounds and methods for detecting ricin and uses thereof
|
|
AT503889B1
(de)
|
2006-07-05 |
2011-12-15 |
Star Biotechnologische Forschungs Und Entwicklungsges M B H F |
Multivalente immunglobuline
|
|
WO2008089339A2
(en)
|
2007-01-18 |
2008-07-24 |
Genzyme Corporation |
Oligosaccharide conjugates for cellular targeting
|
|
PL3219795T3
(pl)
|
2008-01-18 |
2024-09-16 |
Biomarin Pharmaceutical Inc. |
Wytwarzanie aktywnych wysoce fosforylowanych ludzkich enzymów sulfatazy lizosomalnej i ich zastosowania
|
|
WO2009137721A2
(en)
|
2008-05-07 |
2009-11-12 |
Zystor Therapeutics, Inc. |
Lysosomal targeting peptides and uses thereof
|
|
CA2773133A1
(en)
|
2009-08-28 |
2011-03-03 |
Edward H. Schuchman |
Dose escalation enzyme replacement therapy for treating acid sphingomyelinase deficiency
|
|
KR102000383B1
(ko)
|
2009-09-29 |
2019-07-15 |
유니버시테이트 젠트 |
만노스-1-포스포-6-만노스 결합의 포스포-6-만노스로의 가수분해
|
|
JP2013507131A
(ja)
|
2009-10-09 |
2013-03-04 |
アーメイゲン・テクノロジーズ・インコーポレイテッド |
Cnsにおけるイズロン酸2−スルファターゼ活性を増加させるための方法および組成物
|
|
CA2803166C
(en)
|
2010-06-25 |
2023-03-07 |
Shire Human Genetic Therapies, Inc. |
Cns delivery of therapeutic agents
|
|
KR20130043165A
(ko)
|
2010-06-25 |
2013-04-29 |
샤이어 휴먼 지네틱 테라피즈 인크. |
이듀로네이트-2-설파타제의 cns 전달을 위한 방법들 및 조성물들
|
|
EP2588490B1
(en)
|
2010-07-02 |
2017-02-22 |
Angiochem Inc. |
Short and d-amino acid-containing polypeptides for therapeutic conjugates and uses thereof
|
|
JP6131190B2
(ja)
|
2010-09-29 |
2017-05-17 |
オキシレイン ユーケー リミテッド |
リン酸化n−グリカンの脱マンノシル化
|
|
CN103154243A
(zh)
|
2010-10-15 |
2013-06-12 |
日本化学研究株式会社 |
糖链的非还原末端为甘露糖残基的糖蛋白的制造方法
|
|
JP5913122B2
(ja)
|
2010-11-08 |
2016-04-27 |
Jcrファーマ株式会社 |
新規発現ベクター
|
|
CN103443125B
(zh)
|
2010-11-30 |
2019-05-03 |
霍夫曼-拉罗奇有限公司 |
低亲和力血脑屏障受体抗体及其用途
|
|
US9206401B2
(en)
|
2010-12-22 |
2015-12-08 |
Fondazione Telethon |
Therapeutic strategies to treat CNS pathology in mucopolysaccharidoses
|
|
WO2012101671A1
(en)
|
2011-01-25 |
2012-08-02 |
Jcr Pharmaceuticals Co., Ltd. |
Method for production of human recombinant iduronate 2-sulfatase
|
|
WO2012136790A1
(en)
*
|
2011-04-07 |
2012-10-11 |
Glaxo Group Limited |
Compositions comprising fusion proteins or conjugates with an improved half -life
|
|
EA201892619A1
(ru)
|
2011-04-29 |
2019-04-30 |
Роше Гликарт Аг |
Иммуноконъюгаты, содержащие мутантные полипептиды интерлейкина-2
|
|
WO2012159164A1
(en)
|
2011-05-23 |
2012-11-29 |
Phylogica Limited |
Method of determining, identifying or isolating cell-penetrating peptides
|
|
LT2714752T
(lt)
|
2011-05-27 |
2018-03-12 |
Amicus Therapeutics, Inc. |
Nukreipiančių peptidų kopuliavimo ant rekombinantinių lizosominių fermentų būdai, skirti lizosominio kaupimo ligų gydymo pagerinimui
|
|
AU2012272815B2
(en)
|
2011-06-22 |
2017-09-07 |
The General Hospital Corporation |
Treatment of proteinopathies
|
|
US20160145589A1
(en)
|
2011-06-24 |
2016-05-26 |
Green Cross Corporation |
Composition and formulation comprising recombinant human iduronate-2-sulfatase and preparation method thereof
|
|
KR101158673B1
(ko)
|
2011-06-24 |
2012-07-03 |
주식회사 지씨바이오 |
재조합 인간 이듀로네이트-2-설파타아제를 포함하는 조성물, 제제 및 이의 제조방법
|
|
CA2842492A1
(en)
|
2011-08-05 |
2013-02-14 |
Bioasis Technologies, Inc. |
P97 fragments with transfer activity
|
|
WO2013055888A2
(en)
|
2011-10-12 |
2013-04-18 |
Synageva Biopharma Corp. |
Recombinant human naglu protein and uses thereof
|
|
CN104145015A
(zh)
|
2011-12-01 |
2014-11-12 |
安吉奥开米公司 |
靶向的溶酶体酶化合物
|
|
US20140335163A1
(en)
|
2011-12-01 |
2014-11-13 |
Angiochem Inc. |
Targeted iduronate-2-sulfatase compounds
|
|
US8486399B2
(en)
|
2011-12-02 |
2013-07-16 |
Armagen Technologies, Inc. |
Methods and compositions for increasing arylsulfatase A activity in the CNS
|
|
US9682129B2
(en)
|
2011-12-23 |
2017-06-20 |
Shire Human Genetic Therapies, Inc. |
Treatment of cognitive impairment of hunter syndrome by intrathecal delivery of iduronate-2-sulfatase
|
|
BR112014024358A8
(pt)
|
2012-03-30 |
2018-01-23 |
Shire Human Genetic Therapies |
administração subcutânea de iduronato-2-sulfatase
|
|
JP5855239B2
(ja)
|
2012-04-23 |
2016-02-09 |
株式会社Nrlファーマ |
ラクトフェリン融合タンパク質及びその製造方法
|
|
JP6279466B2
(ja)
|
2012-04-27 |
2018-02-14 |
Jcrファーマ株式会社 |
新規な発現ベクター
|
|
WO2013177062A2
(en)
|
2012-05-21 |
2013-11-28 |
Genentech, Inc. |
Methods for improving safety of blood-brain barrier transport
|
|
US20130323221A1
(en)
|
2012-05-30 |
2013-12-05 |
Biostrategies LC |
Plant lectins as carriers of associated drug substances into animal and human cells
|
|
SG11201407017WA
(en)
|
2012-06-04 |
2014-12-30 |
Irm Llc |
Site-specific labeling methods and molecules produced thereby
|
|
WO2013185235A1
(en)
|
2012-06-15 |
2013-12-19 |
Angiochem Inc. |
Targeted iduronidase compounds
|
|
US20140004097A1
(en)
|
2012-06-29 |
2014-01-02 |
Shire Human Genetic Therapies, Inc. |
Method of producing recombinant iduronate-2-sulfatase
|
|
US9150841B2
(en)
|
2012-06-29 |
2015-10-06 |
Shire Human Genetic Therapies, Inc. |
Cells for producing recombinant iduronate-2-sulfatase
|
|
KR101380740B1
(ko)
|
2012-06-29 |
2014-04-11 |
쉐어 휴먼 제네텍 세러피스, 인코포레이티드 |
이듀로네이트-2-설파타제의 정제
|
|
WO2014022515A1
(en)
|
2012-07-31 |
2014-02-06 |
Bioasis Technologies, Inc. |
Dephosphorylated lysosomal storage disease proteins and methods of use thereof
|
|
US10138474B2
(en)
|
2012-08-17 |
2018-11-27 |
Research Foundation Of The City University Of New York |
Scavenger receptor uptake for fabry disease enzyme replacement therapy
|
|
MX367126B
(es)
|
2012-08-29 |
2019-08-06 |
Hoffmann La Roche |
Transporte para atravesar la barrera hematoencefálica.
|
|
WO2014082080A2
(en)
|
2012-11-26 |
2014-05-30 |
Callidus Biopharma, Inc. |
Methods for coupling targeting peptides onto recombinant lysosomal enzymes for improved treatments of lysosomal storage diseases
|
|
ES2679374T3
(es)
|
2012-11-27 |
2018-08-24 |
Biomarin Pharmaceutical Inc. |
Proteínas de fusión terapéuticas dirigidas de enzima lisosómica y usos de las mismas
|
|
CN104955946A
(zh)
|
2012-11-30 |
2015-09-30 |
安吉奥开米公司 |
靶向的艾杜糖醛酸-2-硫酸酯酶化合物
|
|
CN105027138B
(zh)
|
2012-12-27 |
2018-01-26 |
施耐德电气It公司 |
可视化气流的系统和方法
|
|
NZ711373A
(en)
|
2013-03-13 |
2020-07-31 |
Bioasis Technologies Inc |
Fragments of p97 and uses thereof
|
|
WO2014152940A1
(en)
|
2013-03-14 |
2014-09-25 |
Shire Human Genetic Therapies, Inc. |
Mrna therapeutic compositions and use to treat diseases and disorders
|
|
SG11201509566RA
(en)
|
2013-05-20 |
2015-12-30 |
Genentech Inc |
Anti-transferrin receptor antibodies and methods of use
|
|
WO2014194427A1
(en)
|
2013-06-06 |
2014-12-11 |
Angiochem Inc. |
Targeted iduronate-2-sulfatase fusion proteins
|
|
MX370570B
(es)
|
2013-06-07 |
2019-12-17 |
Genzyme Corp |
Marcador para trastornos de la esfingomielinasa acida y sus usos.
|
|
WO2015009052A1
(ko)
*
|
2013-07-16 |
2015-01-22 |
일동제약 주식회사 |
하이브리드 면역글로불린 fc와 효소의 융합단백질
|
|
US10906981B2
(en)
|
2013-07-19 |
2021-02-02 |
The Regents Of The University Of California |
Compositions and methods related to structures that cross the blood brain barrier
|
|
US20150023956A1
(en)
|
2013-07-22 |
2015-01-22 |
Armagen Technologies, Inc. |
Methods and compositions for increasing enzyme activity in the cns
|
|
US20150093399A1
(en)
|
2013-08-28 |
2015-04-02 |
Bioasis Technologies, Inc. |
Cns-targeted conjugates having modified fc regions and methods of use thereof
|
|
EP3041865A2
(en)
|
2013-09-03 |
2016-07-13 |
NovImmune S.A. |
Readily isolated bispecific binding molecules with native format having mutated constant regions
|
|
JP6309427B2
(ja)
|
2013-10-09 |
2018-04-11 |
Jcrファーマ株式会社 |
イズロン酸−2−スルファターゼの活性測定法
|
|
JP6616189B2
(ja)
|
2013-12-25 |
2019-12-04 |
Jcrファーマ株式会社 |
血液脳関門を通過する新規抗トランスフェリン受容体抗体
|
|
WO2015101586A1
(en)
|
2014-01-03 |
2015-07-09 |
F. Hoffmann-La Roche Ag |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
|
PL3092251T3
(pl)
|
2014-01-06 |
2021-08-02 |
F. Hoffmann-La Roche Ag |
Jednowartościowe moduły transportera wahadłowego przez barierę krew-mózg
|
|
AU2015219339B2
(en)
|
2014-02-19 |
2020-03-05 |
Bioasis Technologies Inc. |
P97-IDS fusion proteins
|
|
SMT201800511T1
(it)
|
2014-04-01 |
2018-11-09 |
Swedish Orphan Biovitrum Ab Publ |
Sulfamidasi modificata e sua produzione
|
|
CA2943890A1
(en)
|
2014-05-01 |
2015-11-05 |
Bioasis Technologies, Inc. |
P97-polynucleotide conjugates
|
|
EP3166626B1
(en)
|
2014-07-11 |
2021-04-28 |
Biostrategies LC |
Materials and methods for treating disorders associated with sulfatase enzymes
|
|
US10068619B1
(en)
|
2014-07-25 |
2018-09-04 |
Western Digital Technologies, Inc. |
Hand held storage device
|
|
WO2016025519A1
(en)
|
2014-08-11 |
2016-02-18 |
Shire Human Genetic Therapies, Inc. |
Mannose-6-phosphate bearing peptides fused to lysosomal enzymes
|
|
PT3215528T
(pt)
|
2014-11-06 |
2019-10-11 |
Hoffmann La Roche |
Variantes da região fc com ligação modificada ao fcrn e métodos de utilização
|
|
JP2017534640A
(ja)
|
2014-11-10 |
2017-11-24 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
アルファ−l−イズロニダーゼ、イズロン酸−2−スルファターゼおよびアルファガラクトシダーゼaの治療用組成物ならびにそれらの使用方法
|
|
MA40954A
(fr)
*
|
2014-11-14 |
2017-09-19 |
Shire Human Genetic Therapies |
Détermination de niveaux de glycosaminoglycane par spectrométrie de masse
|
|
CA2967830A1
(en)
|
2014-11-14 |
2016-05-19 |
Ossianix, Inc. |
Tfr selective binding compounds and related methods
|
|
EP3221361B1
(en)
|
2014-11-19 |
2021-04-21 |
Genentech, Inc. |
Anti-transferrin receptor / anti-bace1 multispecific antibodies and methods of use
|
|
JP6779876B2
(ja)
*
|
2014-11-19 |
2020-11-04 |
ジェネンテック, インコーポレイテッド |
抗トランスフェリン受容体抗体及びその使用方法
|
|
MA41198A
(fr)
|
2014-12-18 |
2017-10-24 |
Shire Human Genetic Therapies |
Essais d'activité enzymatique pour i2s
|
|
US10538589B2
(en)
|
2015-01-14 |
2020-01-21 |
Armagen Inc. |
Methods and compositions for increasing N-acetylglucosaminidase (NAGLU) activity in the CNS using a fusion antibody comprising an anti-human insulin receptor antibody and NAGLU
|
|
EP3253884B1
(en)
|
2015-02-05 |
2020-03-18 |
R.P. Scherer Technologies, LLC |
Activated formylglycine-generating enzymes and methods of producing and using the same
|
|
WO2016191869A1
(en)
|
2015-06-01 |
2016-12-08 |
The Hospital For Sick Children |
Delivery of structurally diverse polypeptide cargo into mammalian cells by a bacterial toxin
|
|
CA2990785C
(en)
|
2015-06-24 |
2024-11-12 |
Jcr Pharmaceuticals Co., Ltd. |
ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
|
|
ES2849248T3
(es)
|
2015-06-24 |
2021-08-17 |
Beumer Group As |
Clasificador de línea
|
|
AU2016282334B2
(en)
*
|
2015-06-24 |
2022-07-21 |
F. Hoffmann-La Roche Ag |
Anti-transferrin receptor antibodies with tailored affinity
|
|
WO2017003270A1
(ko)
|
2015-07-02 |
2017-01-05 |
주식회사 녹십자 |
헌터증후군 치료제 및 치료방법
|
|
KR20170004814A
(ko)
|
2015-07-02 |
2017-01-11 |
주식회사 녹십자 |
헌터증후군 치료제
|
|
WO2017055586A1
(en)
|
2015-10-01 |
2017-04-06 |
Swedish Orphan Biovitrum Ab (Publ) |
Modified iduronate 2-sulfatase and production thereof
|
|
JP2018535654A
(ja)
|
2015-10-01 |
2018-12-06 |
スウェディッシュ オーファン バイオビトラム アクティエボラーグ (ペーウーベーエル) |
修飾リソソームタンパク質とその製造
|
|
WO2017062666A2
(en)
|
2015-10-06 |
2017-04-13 |
Patricia Dickson |
Enzyme replacement therapy for mucopolysaccharidosis iiid
|
|
US20180221459A1
(en)
|
2015-10-06 |
2018-08-09 |
LA BioMedical Research Institute at Harbor-UCLA Medical Center |
Enzyme replacement therapy for mucopolysaccharidosis iiid
|
|
MY207684A
(en)
|
2015-12-08 |
2025-03-12 |
Regeneron Pharma |
Compositions and methods for internalizing enzymes
|
|
GB201522243D0
(en)
|
2015-12-16 |
2016-01-27 |
Ucl Business Plc |
Treatment
|
|
HK1258054A1
(zh)
|
2015-12-30 |
2019-11-01 |
株式会社绿十字 |
用於治疗亨特综合征的方法和组合物
|
|
AR107483A1
(es)
|
2016-01-29 |
2018-05-02 |
Hanmi Pharm Ind Co Ltd |
Conjugado de enzimas terapéuticas
|
|
EP3419651B1
(en)
|
2016-02-24 |
2023-10-25 |
BioMarin Pharmaceutical Inc. |
Improved naglu fusion protein formulation
|
|
WO2017151791A1
(en)
|
2016-03-01 |
2017-09-08 |
Biostrategies LC |
Materials and methods for mitigating immune-sensitization
|
|
US11253612B2
(en)
|
2016-04-15 |
2022-02-22 |
The Trustees Of The University Of Pennsylvania |
Gene therapy for treating mucopolysaccharidosis type II
|
|
US10169252B2
(en)
|
2016-07-15 |
2019-01-01 |
International Business Machines Corporation |
Configuring functional capabilities of a computer system
|
|
CA3033082A1
(en)
|
2016-08-06 |
2018-02-15 |
Ossianix, Inc. |
In vivo methods for selecting peptides that cross the blood brain barrier, related compositions and methods of use
|
|
CN109641971B
(zh)
|
2016-08-25 |
2023-04-04 |
Jcr制药股份有限公司 |
抗体融合蛋白的制造方法
|
|
EP3556399A1
(en)
|
2016-12-19 |
2019-10-23 |
Hanmi Pharm. Co., Ltd. |
Brain targeting long-acting protein conjugate
|
|
TWI833178B
(zh)
*
|
2016-12-26 |
2024-02-21 |
日商Jcr製藥股份有限公司 |
通過血腦障壁之新穎抗人類運鐵蛋白受體抗體
|
|
MX2019007824A
(es)
|
2016-12-28 |
2019-09-09 |
Japan Chem Res |
Preparacion liofilizada.
|
|
GB201701968D0
(en)
|
2017-02-07 |
2017-03-22 |
Univ Manchester |
Gene therapy
|
|
RS63818B1
(sr)
|
2017-02-17 |
2023-01-31 |
Denali Therapeutics Inc |
Konstruisani polipeptidi za vezivanje za receptor transferina
|
|
CA3053379A1
(en)
*
|
2017-02-17 |
2018-08-23 |
Denali Therapeutics Inc. |
Anti-tau antibodies and methods of use thereof
|
|
EP4628586A3
(en)
|
2017-02-17 |
2026-01-14 |
Denali Therapeutics Inc. |
Transferrin receptor transgenic models
|
|
CA3053381A1
(en)
|
2017-02-17 |
2018-08-23 |
Denali Therapeutics Inc. |
Engineered polypeptides
|
|
JP7106289B2
(ja)
|
2017-02-21 |
2022-07-26 |
Jcrファーマ株式会社 |
グリコサミノグリカンの分析法
|
|
GB201702863D0
(en)
|
2017-02-22 |
2017-04-05 |
Evox Therapeutics Ltd |
Improved loading of EVs with therapeutic proteins
|
|
WO2019009884A1
(en)
|
2017-07-03 |
2019-01-10 |
Mark Anthony Allen |
VISUAL DRIVING AID FOR VEHICLE VISOR
|
|
US20200157172A1
(en)
|
2017-07-07 |
2020-05-21 |
HANMl PHARM. CO., LTD. |
Novel therapeutic enzyme fusion protein and use thereof
|
|
KR20190013615A
(ko)
|
2017-07-28 |
2019-02-11 |
한미약품 주식회사 |
이두로네이트 2-설파타제 결합체
|
|
WO2019032955A1
(en)
|
2017-08-10 |
2019-02-14 |
Denali Therapeutics Inc. |
MODIFIED TRANSFERRIN RECEPTOR BINDING POLYPEPTIDES
|
|
WO2019049967A1
(ja)
|
2017-09-07 |
2019-03-14 |
Jcrファーマ株式会社 |
水性医薬組成物
|
|
BR112020005271A2
(pt)
|
2017-10-02 |
2020-09-15 |
Denali Therapeutics Inc. |
proteína, polipeptídeo, polinucleotídeo, vetor, célula hospedeira, método para produção de um polipeptídeo, métodos de tratamento de um distúrbio, de diminuição do acúmulo, de monitoramento, de transporte de um agente e de tratamento de um lsd e composição farmacêutica
|
|
WO2019094608A1
(en)
|
2017-11-08 |
2019-05-16 |
Denali Therapeutics Inc. |
Anti-bace1 antibodies and methods of use thereof
|
|
BR112020013921A2
(pt)
|
2018-01-10 |
2020-12-01 |
Denali Therapeutics Inc. |
polipeptídeos de ligação ao receptor de transferrina e usos destes
|
|
WO2019246071A1
(en)
|
2018-06-18 |
2019-12-26 |
Denali Therapeutics Inc. |
Fusion proteins comprising progranulin
|
|
CA3109763A1
(en)
|
2018-08-16 |
2020-02-20 |
Denali Therapeutics Inc. |
Engineered bispecific proteins
|
|
EP3840781A1
(en)
|
2018-08-22 |
2021-06-30 |
Denali Therapeutics Inc. |
Anti-her2 polypeptides and methods of use thereof
|
|
KR20200094577A
(ko)
|
2019-01-30 |
2020-08-07 |
주식회사 모비스 |
인공신경망 시뮬레이터와 강화학습 제어기를 사용한 실시간 가속기 제어 시스템
|
|
AU2020252554B2
(en)
|
2019-04-03 |
2026-05-28 |
Denali Therapeutics Inc. |
Formulations of protein molecules comprising iduronate 2-sulfatase
|
|
BR112022012230A2
(pt)
|
2019-12-23 |
2022-08-30 |
Denali Therapeutics Inc |
Variantes de progranulina
|
|
WO2021146256A1
(en)
|
2020-01-13 |
2021-07-22 |
Denali Therapeutics Inc. |
Anti-trem2 antibodies and methods of use thereof
|
|
US11124567B2
(en)
|
2020-01-13 |
2021-09-21 |
Denali Therapeutics Inc. |
Anti-TREM2 antibodies and methods of use thereof
|
|
WO2021158986A1
(en)
|
2020-02-07 |
2021-08-12 |
Denali Therapeutics Inc. |
Methods for the treatment of hunter syndrome
|
|
CR20230178A
(es)
|
2020-10-14 |
2023-07-26 |
Denali Therapeutics Inc |
Proteínas de fusión que comprenden enzimas sulfoglucosamina sulfohidrolasa y métodos de estas
|